Jefferies analyst Andrew Tsai said new epilepsy drug's sales trajectory bodes well ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE